LQDA, US53635D2027

Liquidia stock: BofA raises target for Liquidia stock to USD 42

Published on 10/22/2026 at 22:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Liquidia's second-quarter revenue reached USD 171.68 million, up 1,842.10 percent year over year. Liquidia stock costs EUR 35.24 on October 22, 2026.

Reporting date November 10, 2026

BofA raised its Liquidia price target from USD 38.00 to USD 42.00 on October 15, 2026.
Liquidia reported second-quarter revenue of USD 171.68 million, up 1,842.10 percent year over year.
Liquidia stock costs EUR 35.24 at Lang & Schwarz on October 22, 2026 at 10:07 p.m. CEST.

LQDA, US53635D2027, Illustration mit AI erstellt.

Liquidia Corporation (US53635D2027) is trading at EUR 35.24 at Lang & Schwarz on October 22, 2026 at 10:07 p.m. CEST. BofA analyst Jason Gerberry raised the price target from USD 38.00 to USD 42.00 on October 15, 2026, while keeping a Neutral rating, Markets Insider reported.

Revenue growth sets the backdrop

Liquidia reported USD 171.68 million in revenue for the second quarter of 2026, compared with USD 132.87 million in the first quarter. That was an increase of 29.22 percent quarter over quarter. The company also reported diluted earnings per share of USD 0.74 and net income attributable to common shareholders of USD 74.72 million for the quarter, according to MarketBeat.

Stock sits below its yearly high

Liquidia's primary listing is Nasdaq, where the stock's USD 21.94 to USD 93.61 52-week range places the latest USD 39.69 quote at 57.60 percent below the high. The market capitalization was USD 3.6 billion on October 22, 2026, and the price-to-earnings ratio was 28.99. These figures frame the analyst target without turning it into a forecast.

November date marks the next test

Liquidia is scheduled to report its next results on November 10, 2026, before the market open, according to Nasdaq. The date follows the second-quarter report published for the period ended June 30, 2026. The company develops inhaled therapies for rare cardiopulmonary diseases, including YUTREPIA for pulmonary arterial hypertension, as described on Liquidia.

What the target says

BofA's USD 42.00 target is USD 2.31 above the latest USD 39.69 Nasdaq quote, an implied distance of 5.82 percent. The separate euro quotation stood at EUR 35.24 at Lang & Schwarz on October 22, 2026 at 10:07 p.m. CEST.

Price and upcoming date

The next earnings date gives investors a defined event to compare with the second-quarter revenue increase and the range of analyst views. Liquidia's cash generation and commercialization progress will remain central to that comparison.

The further course of trading is shown by the continuously updated real-time quote of Liquidia stock.